At the time, the SEC had the authority to bring anti-fraud actions after investors lost money but had no power to require full disclosure from state and local governments to enlighten investors about prospective bond offerings.
Moreover, its best-selling anti-allergy drug, Claritin, lost patent protection last year and the firm's various strategies to maintain market share have yet to show results.